Home  »  Equity Investing   »  Liquidia Corporation (LQDA) Stock Picked up in the...

Liquidia Corporation (LQDA) Stock Picked up in the Aftermarket, Here’s why.

Liquidia Corporation (LQDA) is an innovative biotherapeutic company which is primarily focused on the development and marketing candidates related to pulmonary hypertension and other applications of its latest PRINT Technology. One of the main product candidates of the company is LIQ861 or Treprostinil-based dry inhalation powder for treating pulmonary arterial hypertension. The company also delivers generic Treprostinil Injection. Another product of the company is LIQ865 used for treating local post-operation pain.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

The price of LQDA stock during the regular trading on January 3, 2022, was $5.14 with an incline of 5.54%. At last check in the aftermarket, the stock was further significantly up by 7.98%.

LQDA: Events and Happenings

On January 03, 2022, LQDA reported about the appointment of Dr. Roger Jeffs the new CEO of the company with immediate effect. His successor was Damian deGoa who will serve as the company’s director and sort out the transition procedure. On December 29, 2021, LQDA reported about the filing of a stipulation of partial judgment regarding Patent No. 9,604,901 by the United Therapeutics Corporation. Under the judgment, UTC had agreed for the entry of judgment of the company’s non-infringement of the ’901 patent based on the Court’s construction of patent’s conditions. The patent served as a basis for the regulatory stay for the final endorsement of YUTREPIA by the FDA.

On November 11, 2021, LQDA reported that the company’s executives provided an update on the company’s business during Virtual Jefferies 2021 London Healthcare Conference held on November 16-19, 2021. On November 08, 2021, LQDA reported that FDA granted cautious approval for YUTREPIA (treprostinil) inhalation powder. The drug had already met the monitoring quality, safety, and efficacy standards of the FDA.

LQDA: Key Financials

On November 03, 2021, LQDA announced financial results for the third quarter ended September 30, 2021. Some of the key highlights are as follows.

Revenue and Assets

Revenue generated during Q3 2020 was nil as compared to the same period of 2021 when it was $3.2 million. The total assets of the company as of the Third quarter of 2021 were $100.2 million.

Net Loss per Share

Basic and diluted net loss for the third quarter of 2021 was $7.3 million, or $0.14 per share, versus a net loss of $15.0 million, or $0.40 per share, for the same period of 2020.

On October 08, 2021, LQDA reported about the ruling in its favor by the Patent Trial and Appeal Board. The ruling was related to the Inter Partes Review scheduled contrary to Patent No. 9,604,901 which was owned by United Therapeutics Corporation. On September 10, 2021, LQDA that the company’s executives presented at the Virtual 23rd Annual H.C. Wainwright Global Investment Conference held on September 13–15, 2021.

Conclusion

The company’s stock inclined remarkably 98% as compared to the past six months which represented its powerful, sound, and excellent business strategies to attract potential investors. The current rise in the aftermarket is the result of the company’s announcement regarding the transition of CEO.

Leave a Comment

Your email address will not be published.

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]